Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 5/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | CA1 | P00915 | 2/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.68 |
| ▸ | CA9 | Q16790 | 2/20 | 0.68 |
| ▸ | CA4 | P22748 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | RECQL | P46063 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | KDM1A | O60341 | 1/20 | 0.66 |
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19283297 | 1.00 | ESRRG (0.72) | ESRRGSMN1; SMN2KMT2AMAPTKDM4E | |
| SCHEMBL19283311 | 0.92 | ESRRG (0.79) | ESRRGSMN1; SMN2KMT2AMAPTKDM4E | |
| SCHEMBL19283313 | 0.92 | ESRRG (0.79) | ESRRGSMN1; SMN2KMT2AMAPTKDM4E | |
| SCHEMBL28900918 | 0.86 | RAB9A (0.74) | ESRRGSMN1; SMN2KMT2AMAPTKDM4E | |
| SCHEMBL13475703 | 0.86 | RAB9A (0.74) | ESRRGSMN1; SMN2KMT2AMAPTKDM4E | |
| SCHEMBL15317961 | 0.86 | RAB9A (0.87) | ESRRGSMN1; SMN2KMT2AMAPTKDM4E | |
| SCHEMBL28484762 | 0.86 | RAB9A (0.74) | SMN1; SMN2KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL19283320 | 0.84 | KMT2A (0.78) | ESRRGSMN1; SMN2KMT2AMAPTKDM4E | |
| SCHEMBL19283319 | 0.84 | KMT2A (0.78) | ESRRGSMN1; SMN2KMT2AMAPTKDM4E | |
| SCHEMBL13791896 | 0.84 | ESRRG (0.74) | ESRRGSMN1; SMN2KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246130-A1 | 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS | CHOUDHARY MUHAMMAD IQBAL (PK) | 2017-08-31 | — | — | US | claimed |
| US-20170246130-A1 | 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS | CHOUDHARY MUHAMMAD IQBAL (PK) | 2017-08-31 | — | — | US | disclosed |
| US-20170246130-A1 | 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS | CHOUDHARY MUHAMMAD IQBAL (PK) | 2017-08-31 | — | — | US | disclosed |
| US-20170246130-A1 | 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS | CHOUDHARY MUHAMMAD IQBAL (PK) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246130-A1 | 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS | TYMP, DPYD, FLT4 | ESRRG 4221/4885SMN1; SMN2 4298/4885KMT2A 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.